|  |  |
| --- | --- |
| DEPARTMENT OF HEALTH SERVICES Division of Care and Treatment Services  F-24277 (09/2016) | STATE OF WISCONSIN 42 CFR483.420(a)(2)  DHS 134.31(3)(o)  DHS 94.03 & 94.09  §§ 51.61(1)(g) & (h) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INFORMED CONSENT FOR MEDICATIONDosage and / or Side Effect information last revised on 10/29/2018 Completion of this form is voluntary. If not completed, the medication cannot be administered without a court order unless in an emergency.  This consent is maintained in the client’s record and is accessible to authorized users. | | | | | | | | | |
| Name – Patient / Client (Last, First MI)       , | | | | | ID Number | | | Living Unit | Date of Birth |
| Name – Individual Preparing This Form | | | Name – Staff Contact | | | | | Name / Telephone Number – Institution | |
| MEDICATION CATEGORY | **MEDICATION** | | | | | RECOMMENDED **DAILY TOTAL DOSAGE RANGE** | | | ANTICIPATED DOSAGE RANGE |
| Antipsychotic Agent | Invega Sustenna  (paliperidone palmitate) | | | | | Intramuscular: 39mg to 234mg monthly | | |  |
| The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference.  This medication will be administered  Orally  Injection  Other – Specify: | | | | | | | | | |
| Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use) Include DSM-5 diagnosis or the diagnostic “working hypothesis.” | | | | | | | | | |
|  | | | | | | | | | |
| **2. Alternative mode(s) of treatment other than OR in addition to medications include** Note: Some of these would be applicable only in an inpatient environment. | | | | | | | | | |
| Environment and/or staff changes | | | | Rehabilitation treatments/therapy (OT, PT, AT) | | | | | |
| Positive redirection and staff interaction | | | | Treatment programs and approaches (habilitation) | | | | | |
| Individual and/or group therapy | | | | Use of behavior intervention techniques | | | | | |
| **Other Alternatives**: | | | | | | | | | |
|  | | | | | | | | | |
| 3. Probable consequences of NOT receiving the proposed medication are | | | | | | | | | |
| Impairment of  Work Activities | | Family Relationships | | | | | Social Functioning | | |
|  | |  | | | | |  | | |
| Possible increase in symptoms leading to potential | | | |  | | | | | |
| Use of seclusion or restraint | | | | Limits on recreation and leisure activities | | | | | |
| Limits on access to possessions | | | | Intervention of law enforcement authorities | | | | | |
| Limits on personal freedoms | | | | Risk of harm to self or others | | | | | |
| Limit participation in treatment and activities | | | |  | | | | | |
| **Other Consequences**: | | | | | | | | | |
| Note: These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered. | | | | | | | | | |

See Page 2

| F-24277 | Medication: Invega Sustenna - (paliperidone palmitate) |
| --- | --- |
| Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment. | |
| Continued – Possible side effects, warnings, and cautions associated with this medication.Most Common Side Effects Most common side effects include rapid heartbeat, changes in heart rhythm, drowsiness, abnormal muscle movements, uncontrolled involuntary movements, headache, increased serum prolactin, increased LDL, cholesterol, and triglycerides, weight gain, elevated blood glucose, vomiting, and tremor. | |
| **Less Common Side Effects**  Less common side effects include lightheadedness, swelling of extremities, agitation, anxiety, dizziness, sleep disorder, skin rash, menstrual period dysregulation, decreased sex drive, heartburn, increased appetite, urinary tract infection, breast tenderness, erectile dysfunction, elevated liver enzymes, swelling at injection site, and blurred vision. | |
| **Rare Side Effects**  Rare side effects include diabetes mellitus, swelling of throat, fainting, urinary incontinence, and difficulty urinating. | |
| **Caution**  **Antiemetic effects:** May mask toxicity of other drugs or conditions (such as intestinal obstruction, Reye’s syndrome, brain tumor) due to antiemetic effects.  **Cardiovascular:** Avoid use in patients with history of cardiac arrhythmias or congenital long QT syndrome due to increased risk of QT interval prolongation or sudden death. Avoid use with other QT-prolonging drugs. Dizziness and/or fainting when standing too quickly have been reported. Use cautiously in patients with cardiovascular or cerebrovascular disease or conditions with risk of low blood pressure (such as dehydration or antihypertensive medications). Monitoring is recommended.  **Discontinuation:** When discontinuing therapy, guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, headache.  **Elderly patients:** Increased risk of movement disorders such as tardive dyskinesia, especially elderly women.  **Endocrine and metabolic:** High blood glucose has been reported, including extreme cases associated with ketoacidosis, hyperosmolar coma, or death. Patients with diabetes mellitus or risk factors have increased risk of worsening of glucose control. Weight gain may occur. Dyslipidemia has been reported. Hyperprolactinemia may occur. Use cautiously among patients with conditions that may contribute to elevated body temperature, such as strenuous exercise, extreme heat exposure, dehydration. Monitoring is recommended.  **Extrapyramidal Symptoms:** Potentially irreversible tardive dyskinesia may occur, with increased risk associated with extended treatment duration and higher cumulative doses. Discontinuation may be necessary.  **Falls:** Falls that may lead to fracture or other injuries may occur as a result of somnolence, low blood pressure upon standing, or motor or sensory instability. Assessment of fall risk is recommended.  **Gastrointestinal:** Esophageal dysmotility and aspiration may occur. Use cautiously in patients at risk for aspiration pneumonia.  **Hematologic:** Myelosuppression (such as agranulocytosis, leukopenia, neutropenia) has been reported, with increased risk among patients with low WBC or history of drug-induced leukopenia or neutropenia. Monitoring is recommended.  **Immunologic:** Anaphylaxis, angioedema, and other hypersensitivity reactions have been reported.  **Neurologic:** Potentially fatal neuroleptic malignant syndrome (NMS) has been reported with use of antipsychotic drugs. Immediately discontinue if NMS is suspected. Close monitoring recommended if therapy reintroduced after resolution. Seizures have been reported. Use cautiously in patients with seizure history or conditions that lower the seizure threshold. Patients with Parkinson disease or dementia with Lewy bodies may experience increased sensitivity to antipsychotic medications. May cause CNS depression, which may impair physical or mental abilities. Use caution when performing tasks that require mental alertness.  **Renal:** Use not recommended among patients with moderate to severe renal impairment. Dose adjustment recommended for patients with mild renal impairment.  **Reproductive:** Painful erections have been reported with oral paliperidone administration. | |
| **Black Box Warning**  **Increased mortality in elderly patients with dementia-related psychosis**  Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of patients with dementia-related psychosis. | |
| See PDR for an all-inclusive list of side effects. | |
| By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:   1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal. 2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements. 3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist. 4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b). 5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance. 6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent. 7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete. 8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose. | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SIGNATURES** | | | | | **DATE SIGNED** |
| Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC) | | | Relationship to Client  Self  Parent  Guardian (POA-HC) | |  |
| Staff Present at Oral Discussion | | | Title | |  |
| Client / Parent of Minor / Guardian (POA-HC) Comments | | | | | |
| **As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.** | | | | |
| **Verbal Consent** | | | | |
| Obtained by – PRINT – Staff Name | Date Obtained | | Written Consent Received Yes  No | |
| Obtained from – PRINT – Parent / Guardian (POA-HC) Name | Date Expires | | Date Received | |